cular overload may first become manifest during emergence from anesthesia when the vasodilatory effects of anesthetic drugs and techniques are dissipated or positive pressure ventilation is discontinued. Hyskon may directly cause a coagulopathy.

Both 1.5% glycine and a premixture of 2.7% sorbitol and 0.54% mannitol are low-viscosity, hypo-osmolar (200 and 178 mOsm per liter, respectively), rapidly metabolized instilling fluids. Excessive absorption can result in substantial hyponatremia and hypo-osmolemia.

A solution of 5% mannitol may have a wider margin of safety compared with the other instilling fluids because it is iso-osmolar (278 mOsm per liter). In fact, mannitol is commonly administered intravenously during neuroanesthesia, often in volumes and concentrations greater than those encountered in operative hysteroscopy and without pathophysiologic sequelae. Excessive intravascular absorption of instilled 5% mannitol solution will cause hyponatremia, but serum osmolarity will not change. Furthermore, mannitol initiates a diuresis that self-corrects volume overload.

Although treatment regimens for hyponatremia, hypo-osmolemia, and circulatory overload are well established, anesthetic management of these otherwise healthy women should emphasize the prevention of the OHIA syndrome and its attendant morbidity and possible mortality.

STEPHEN JACKSON, MD
GEORGE LAMPE, MD
San Jose, California

REFERENCES

Arieff AI, Ayus JC: Endometrial ablation complicated by fatal hyponatremic encephalopathy. JAMA 1993; 270:1230-1232

Baggish MS, Brill AI, Rosenzweig B, Barbot JE, Indman PD: Fatal acute glycine and sorbitol toxicity during operative hysteroscopy. J Gynecol Surg 1993; 9:137-143

Witz CA, Silverberg KM, Burns WN, Schenken RS, Olive DL: Complications associated with the absorption of hysteroscopic fluid media. Fertil Steril 1993; 60:745-766

Desflurane—A New Inhalation Anesthetic

BEFORE 1993, three volatile inhalation anesthetics were in routine use. These inhalation anesthetics—halothane, enflurane, and isoflurane—have many desirable qualities. As the number of outpatient procedures continues to increase, recent emphasis in anesthetic practice has been toward the development of agents that provide more rapid recovery. A new inhalation anesthetic, desflurane, provides more precise control during delivery and more rapid recovery than preexisting inhalation anesthetics. These improved properties result from its low blood-gas solubility coefficient, which promotes more rapid induction and emergence from anesthesia. This blood-gas solubility coefficient is 0.45, which is similar to cyclopropane (0.42) and nitrous oxide (0.47) and less than half that of isoflurane (1.4). Sevoflurane is another new inhalational agent that has a low solubility coefficient (0.60), but it is still undergoing clinical trials for approval by the Food and Drug Administration.

Desflurane was recently released for clinical use in the United States. Because its high vapor pressure at 20°C is 669 mm of mercury, desflurane is near its boiling point at room temperature. Accurate delivery must be accomplished by using a heated vaporizer that maintains its near-constant temperature, converting desflurane to a gas and then blending this gas with fresh gas flow. In addition to its lower blood-gas solubility, another of desflurane's attractive properties is its low level of biotransformation in the body. Many of the toxicities attributed to earlier inhalation anesthetics are caused by metabolites from hepatic biotransformation. Desflurane is biotransformed at less than an eighth the rate of isoflurane, which previously had been the least biotransformed inhalation agent. In addition, it has excellent physical stability. Its effect on vital organ systems, when higher concentrations are used, is similar to that of existing inhalation agents. It depresses ventilation, lowers mean arterial pressure, and causes some cerebral vasodilation.

Desflurane differs from sevoflurane in several ways: it is stable in carbon dioxide absorbents where sevoflurane has some instability, it undergoes much less hepatic biotransformation than sevoflurane, it may produce a tachycardia at higher concentrations, and its pungency produces airway irritation that precludes its use for inhalation inductions in children.

Desflurane should not produce hepatotoxicity of the form observed with halothane. Although it is not perfect, it does appear to offer specific advantages over previous agents. Cost-benefit comparisons with existing inhalational agents will be another important consideration.

EDWARD J. FRINK Jr, MD
Tucson, Arizona

REFERENCES

Eger EI II: Desflurane: An overview of its properties. Anesthesiol Rev 1993; 20:87-92

Tsai S, Lee C, Kwan WF, Chen BJ: Recovery of cognitive functions after anaesthesia with desflurane or isoflurane and nitrous oxide. Br J Anaesth 1992; 69:255-258

Intraspinal Narcotics for Obstetric Analgesia

THE USE OF intraspinal narcotics has found widespread acceptance in obstetric analgesia, but has generally been confined to epidural administration. A better understanding of the pharmacology of narcotics and advances in the equipment available have led to the increasing use of intrathecal narcotics in labor. This technique is now a reasonable alternative for women in early labor, in particular, and perhaps a cost-effective alternative in obstetric centers without full-time "in-house" obstetric anesthesia services.

The early use of intrathecal morphine sulfate for labor was effective, but the side effects of pruritus, nausea, and vomiting and the limitations of a single injection (that is, no easy route for further intervention) and its slow onset (30 to 90 minutes) led to its near abandonment. The technique was recently "reinvented," however. The problem of a slow onset was solved by adding one of the lipid-